Mounjaro®
Starting from £179.99/mo
Start journey Learn moreYou can follow a ketogenic diet while taking Wegovy, and some people do — but whether it is the right choice depends on your individual circumstances, how your body responds, and what your prescriber thinks. Semaglutide and keto both reduce appetite and alter how your body uses energy, which means combining them needs thought, not just enthusiasm. Wegovy (semaglutide) is a prescription-only medicine licensed in the UK for weight management in adults with a qualifying BMI; a prescriber assesses whether it is clinically suitable for you before treatment begins. So the question of keto on Wegovy is really a decision, not a simple yes or no, and this page maps out the factors that should shape it.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
The appeal is understandable. You are already working to reduce your appetite on Wegovy; keto cuts carbohydrates sharply, which tends to reduce hunger independently. Both approaches shift the body away from relying on blood glucose as its main fuel. If one is good, two must be better, that is the reasoning many people arrive with, and it is not entirely wrong.
There is genuine overlap. Ketogenic eating does reduce insulin levels and promotes fat oxidation. Semaglutide reduces caloric intake by slowing how quickly food leaves your stomach and signalling fullness to the brain. Neither requires the other to work, but they do not cancel each other out either. Some people find that starting Wegovy makes very-low-carb eating easier to stick to, simply because the urge to reach for carbohydrate-dense comfort foods diminishes on the medicine.
What the clinical literature on eating patterns during Wegovy treatment consistently shows is that overall caloric deficit and adequate protein are what matter most for body composition. The macronutrient split (whether keto, Mediterranean, or anything else) is secondary to those two. That context does not make keto wrong; it does mean keto is not a requirement, and that its costs deserve honest attention alongside its perceived benefits. Our Wegovy overview covers the trial evidence in more detail if you want to understand what the 68-week STEP 1 data actually measured.
Gastrointestinal effects are the most common reason people struggle on Wegovy, particularly in the early weeks of treatment or after a dose increase. Nausea, constipation and feelings of fatigue are reported frequently. A ketogenic diet (especially in its first week or two) brings its own transition effects: the so-called keto flu, which includes headaches, fatigue, irritability and constipation. Starting or intensifying both at the same time layers one set of physiological stressors on top of another, and many people find that harder to tolerate than either change alone.
Constipation is worth particular attention. Reduced food volume, low fibre from cutting out many carbohydrate-containing plants, and semaglutide's effect on gut motility can combine to make bowel habits genuinely uncomfortable. Increasing non-starchy vegetables, staying well hydrated, and discussing fibre strategies with your prescriber can help, but it is worth knowing the risk going in, not discovering it mid-treatment.
Electrolyte balance is another consideration. Ketogenic diets prompt significant water and sodium loss early on; semaglutide-related nausea and reduced food intake can compound dehydration risk. Anyone feeling dizzy, very fatigued, or experiencing muscle cramps should not assume this is normal and push through, those are signals to contact their clinical team. You can read about how semaglutide and low-carb eating interact in more depth on a dedicated page.
One of the less-discussed risks of GLP-1 treatment is the loss of muscle mass alongside fat. When appetite drops substantially, total food intake falls, and if protein does not remain a deliberate priority, the body may draw on muscle protein during rapid weight loss. Clinical guidance consistently suggests that people on Wegovy should aim for adequate protein at each meal and treat it as a non-negotiable, not an afterthought.
Ketogenic diets are sometimes high in protein, but they can equally be dominated by fat, with protein moderate or even low depending on how the person structures their eating. On a very small appetite (which Wegovy can produce, especially approaching maintenance doses) there may simply not be room in a day's meals to hit both a ketogenic fat threshold and a meaningful protein target. Protein generally needs to come first, at each sitting, before fat and incidental carbohydrate.
This is one reason that practical meal planning on Wegovy tends to lean toward protein-forward structures that happen to be moderate in carbohydrates, rather than rigidly ketogenic ones. That said, for someone already adapted to keto who manages protein well, the transition can be smoother. Context and habit matter.
The question of whether to follow a ketogenic diet alongside semaglutide is genuinely individual. There is no blanket answer because the variables (your starting health, your history with keto, your current dose, your tolerance of side effects, and your ability to maintain protein intake) differ from one person to the next.
What is clear is that the order in which you introduce changes matters. Many prescribers suggest settling into Wegovy first: let your body adjust to semaglutide's effects over four to eight weeks before making further significant dietary changes. Attempting a dramatic dietary overhaul at the same time as starting a new prescription medicine makes it difficult to understand what is causing what, and harder to manage problems if they arise.
If you are already established on keto and want to start Wegovy, that is a different conversation, one worth having openly with your prescriber so they can adjust their monitoring and advice accordingly. For anyone wondering whether a particular approach to eating is appropriate given their health history, the free consultation at nume is the place to start that conversation. A prescriber reviews every case personally and can factor your dietary approach into their clinical assessment.
There is also a practical note on what Wegovy actually does to food preferences. Many people report that sweet and starchy foods become less appealing on the medicine, which can make a lower-carbohydrate pattern feel natural rather than effortful. Whether that tips into a fully ketogenic range is something to monitor rather than mandate, and if you are curious about whether Wegovy itself pushes the body into ketosis, that question is covered separately and is worth reading before drawing conclusions about how much dietary carbohydrate restriction is actually needed. Checking in with your clinical team if your eating shifts significantly is always sensible. More on the broader question of food choices on Wegovy is worth reading alongside this page.
The NHS medicines page for semaglutide covers the clinical side effects and dietary guidance in plain terms, and the NHS England guidance on weight management injections explains the wraparound support that is expected alongside this type of treatment.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.